Asset profile

maridebart cafraglutide · MariTide

Peptide

Phase 3underway

Evidence outlook · registrational

Atherosclerotic Cardiovascular Disease: registrational readout pending

Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2028-06-30.

Also in development:Obesity · Phase 3Heart Failure · Phase 3

How the evidence outlook works ↗

Upcoming events

(11 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2027 (8)
January 2027 (2)
Phase 3ObesityActive not recruiting
Est. primary completion 2027-01-21 · NCT06858839 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3ObesityActive not recruiting
Est. primary completion 2027-01-21 · NCT06858878 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2027 (1)
Phase 3ObesityActive not recruiting
Est. primary completion 2027-04-27 · NCT06987695 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2027 (3)
Phase 2ObesityRecruiting
Est. primary completion 2027-09-29 · NCT07441252 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3ObesityRecruiting
Est. primary completion 2027-09-29 · NCT07225686 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Obstructive Sleep ApneaRecruiting
Est. primary completion 2027-09-29 · NCT07226765 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (2)
Phase 3ObesityNot yet recruiting
Est. primary completion 2027-12-26 · NCT07684144 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3ObesityRecruiting
Est. primary completion 2027-12-26 · NCT07684235 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (3)
January 2028 (1)
Phase 3ObesityRecruiting
Est. primary completion 2028-01-03 · NCT07575399 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2028 (2)
Phase 3ObesityRecruiting
Est. primary completion 2028-06-30 · NCT07037459 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Atherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2028-06-30 · NCT07037433 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.